�������ýҕ�l

AstraZeneca Plc said its blood-cancer medicine Calquence failed to help patients hospitalized with respiratory symptoms of Covid-19. The group of patients taking the drug in addition to standard care didn’t show fewer deaths or respiratory failures, the U.K. drugmaker said in a statement. Details of the intermediate clinical trials will be presented in due course, the company said. (Fourcade, 11/12)

A novel clinical trial that uses artificial intelligence to rapidly compare Covid-19 treatments has attracted participation from two major drug companies, a key milestone in the effort to shake up the way trials are conducted. (Ross, 11/10)

Dozens of members of Congress are urging the U.S. Department of Justice to revise a recent $8.3 billion settlement of civil and criminal charges with Purdue Pharma, arguing that one part of the deal is really a “mirage” designed to help lessen the financial burden for the Sackler family, which controls the company. In a sharply worded letter, the lawmakers objected to the idea of transforming the drug maker into a public benefit company. (Silverman, 11/11)

An experimental medicine from AstraZeneca and Amgen significantly reduced the frequency of asthma attacks when added to standard treatment, achieving the goals of a late-stage clinical trial involving patients with severe asthma, the companies announced Tuesday. (Feuerstein, 11/10)

Gene therapies hold huge promise for inherited diseases that attack the nervous system — but studies show they can inadvertently damage sensitive nerve cells, triggering side effects like weakness, numbness, and intense pain. (Keshavan, 11/11)